Enjeksiyon

Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanima Hazir Kalem

Risankizumab Enjeksiyonluk Reçete durumu belirtilmemiş

Abbvie Tibbi İlaçlar San. ve Tic. Ltd. Şti.

Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanima Hazir Kalem Nedir ve Ne İçin Kullanılır?

1 \000. \0008 \000/ \000/ \000$ \0001 \0000 \000$ \000 \0007 \000$ \000/ \000? \0000 \000$ \0007 \000, \000 \0006 \000. \000< \0005 \000, \000= \000, \000 \000 \000 \000 \000 \000P \000J \000 \000P \000/ \000 \000H \000Q \000M \000H \000N \000V \000L \000\\ \000R \000Q \000O \000X \000N \000 \000o \000| \000] \000H \000O \000W \000L \000 \000L \000o \000H \000U \000H \000Q \000 \000N \000X \000O \000O \000D \000Q \000? \000P \000D \000 \000K \000D \000] \000? \000U \000 \000N \000D \000O \000H \000P \000 \000 Steril \000' \000H \000U \000L \000 \000D \000O \000W \000? \000Q \000D \000 \000H \000Q \000M \000H \000N \000V \000L \000\\ \000R \000Q \000 \000\\ \000R \000O \000X \000\\ \000O \000D \000 \000X \000\\ \000J \000X \000O \000D \000Q \000? \000U \000 \000

? \000+ \000H \000U \000 \000E \000L \000U \000 \000N \000X \000O \000O \000D \000Q \000? \000P \000D \000 \000K \000D \000] \000? \000U \000 \000N \000D \000O \000H \000P \000 \000 \000 \000 \000P \000/ \000 \000o \000| \000] \000H \000O \000W \000L \000G \000H \000 \000 \000 \000 \000 \000P \000J \000 \000U \000L \000V \000D \000Q \000N \000L \000] \000X \000P \000D \000E \000 \000L \000o \000H \000U \000L \000U \000 \000 Etkin madde: ? \000< \000D \000U \000G \000? \000P \000F \000? \000 \000P \000D \000G \000G \000H \000O \000H \000U \000 \000 Sodyum asetat trihidrat \(E262\, asetik asit \(E260\, trehaloz dihidrat, polisorbat 20, enjeksiyonluk su.

\000% \000X \000 \000L \000O \000D \000o \000 \000H \000N \000 \000L \000] \000O \000H \000P \000H \000\\ \000H \000 \000W \000D \000E \000L \000G \000L \000U \000 \000 \000% \000X \000 \000? \000o \000J \000H \000Q \000 \000\\ \000H \000Q \000L \000 \000J \000? \000Y \000H \000Q \000O \000L \000O \000L \000N \000 \000E \000L \000O \000J \000L \000V \000L \000Q \000L \000Q \000 \000K \000? \000] \000O \000? \000 \000R \000O \000D \000U \000D \000N \000 \000E \000H \000O \000L \000U \000O \000H \000Q \000P \000H \000V \000L \000Q \000L \000 \000V \000D \000? \000O \000D \000\\ \000D \000F \000D \000N \000W \000? \000U \000 \000 \0000 \000H \000\\ \000G \000D \000Q \000D \000 \000J \000H \000O \000H \000Q \000 \000K \000H \000U \000K \000D \000Q \000J \000L \000 \000E \000L \000U \000 \000\\ \000D \000Q \000 \000H \000W \000N \000L \000\\ \000L \000 \000U \000D \000S \000R \000U \000O \000D \000\\ \000D \000U \000D \000N \000 \000\\ \000D \000U \000G \000? \000P \000F \000? \000 \000R \000O \000D \000E \000L \000O \000L \000U \000V \000L \000Q \000L \000] \000 \000 \000< \000D \000Q \000 \000H \000W \000N \000L \000O \000H \000U \000L \000Q \000 \000Q \000D \000V \000? \000O \000 \000U \000D \000S \000R \000U \000O \000D \000Q \000D \000F \000D \000? \000? \000Q \000? \000 \000| \000? \000U \000H \000Q \000P \000H \000N \000 \000L \000o \000L \000Q \000 \000 \000 \000 \000% \000| \000O \000? \000P \000? \000Q \000 \000V \000R \000Q \000X \000Q \000D \000 \000E \000D \000N \000D \000E \000L \000O \000L \000U \000V \000L \000Q \000L \000] \000

\000% \000X \000 \000. \000X \000O \000O \000D \000Q \000P \000D \000 \0007 \000D \000O \000L \000P \000D \000W \000? \000Q \000G \000D : \000 \000 \000 \0006 \000. \000< \0005 \000, \000= \000, \000 \000Q \000H \000G \000L \000U \000 \000Y \000H \000 \000Q \000H \000 \000L \000o \000L \000Q \000 \000N \000X \000O \000O \000D \000Q \000? \000O \000? \000U \000" \000 2. SKYRIZI?yi kullanmadan ?nce dikkat edilmesi gerekenler \000 \000 \000 \0006 \000. \000< \0005 \000, \000= \000, \000 \000Q \000D \000V \000? \000O \000 \000N \000X \000O \000O \000D \000Q \000? \000O \000? \000U \000" \000 \000 \000 \000 \0002 \000O \000D \000V \000? \000 \000\\ \000D \000Q \000 \000H \000W \000N \000L \000O \000H \000U \000 \000Q \000H \000O \000H \000U \000G \000L \000U \000" \000 \000 \000 \000 \0006 \000. \000< \0005 \000, \000= \000, \000? \000Q \000L \000Q \000 \000V \000D \000N \000O \000D \000Q \000P \000D \000V \000? \000 \000% \000D \000? \000O \000? \000N \000O \000D \000U \000? \000 \000\\ \000H \000U \000 \000D \000O \000P \000D \000N \000W \000D \000G \000? \000U \000 \000

\000 \000 \000 \0006 \000. \000< \0005 \000, \000= \000, \000 \000Q \000H \000G \000L \000U \000 \000Y \000H \000 \000Q \000H \000 \000L \000o \000L \000Q \000 \000N \000X \000O \000O \000D \000Q \000? \000O \000? \000U \000" \000 \000W \000H \000N \000Q \000R \000O \000R \000M \000L \000V \000L \000 \000D \000G \000? \000 \000Y \000H \000U \000L \000O \000H \000Q \000 \000E \000L \000U \000 \000W \000H \000N \000Q \000L \000N \000 \000N \000X \000O \000O \000D \000Q \000? \000O \000D \000U \000D \000N \000 \000o \000L \000Q \000 \000K \000D \000P \000V \000W \000H \000U \000L \000 \000K \000? \000F \000U \000H \000O \000H \000U \000L \000Q \000G \000H \000 \000? \000U \000H \000W \000L \000O \000H \000Q \000 \000 \000L \000Q \000W \000H \000U \000O \000| \000N \000L \000Q \000 \000 \000, \000/ \000\f \000 \000 \000 \000 \000S \000U \000R \000W \000H \000L \000Q \000L \000Q \000H \000

Eşdeğer İlaçlar (Aynı Etken Madde)

Sıkça Sorulan Sorular

Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanima Hazir Kalem ne için kullanılır?
1 \000. \0008 \000/ \000/ \000$ \0001 \0000 \000$ \000 \0007 \000$ \000/ \000? \0000 \000$ \0007 \000, \000 \0006 \000. \000< \0005 \000, \000= \000, \000 \000 \000 \000 \000 \000P \000J \000 \000P \000/ \000 \000H \000Q \000M \000H \000N \000V \000L \000\\ \000R \000Q \000O \000X \000N \000 \000o \000| \000] \000H \000O \000W \000L \000 \000L \000o \000H \000U \000H \000Q \000 \000N \000X \000O \000O \000D \000Q \000? \000P \000D \000 \000K \000D \000] \000?
Kaynak: T.C. Sağlık Bakanlığı TİTCK Kısa Ürün Bilgisi & Kullanma Talimatı. Bu içerik yalnızca bilgilendirme amaçlıdır, hekim tavsiyesi yerine geçmez.